results of capitello291 - capivasertib
Published 6 months ago • 101 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
21:42
dr. hope rugo discusses capivasertib fda approval based on capitello-291 study
-
0:52
background on capivasertib - now approved for breast cancer
-
0:49
how prevalent are akt pathway alterations in breast cancer?
-
5:28
capitello-291: capivasertib fulvestrant for ai-resistant hr /her2- advanced breast cancer
-
0:59
ribociclib in adjuvant hr breast cancer
-
0:53
picking the right cdk 4/6 inhibitor upfront for metastatic breast cancer.
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
0:55
role of chemotherapy in early hormone receptor-positive breast cancer
-
0:54
nsabp b-51: can we forego radiation in early breast cancer? | #cancer #oncology
-
1:00
2nd line treatment options for hr breast cancer.
-
0:38
inclusion criteria for natalee trial - evaluating importance of ajuvant ribociclib #oncology #cancer
-
22:08
breast cancer asco 2024 practice changing highlights - discussion with dr. erika hamilton
-
0:29
adjuvant treatment for high risk hr breast cancer | esmo 2023 breast cancer highlights
-
0:59
how to sequence adcs in breast cancer? | esmo 2023 breast cancer highlights
-
0:58
treatment approach for metastatic her2 positive breast cancer
-
1:00
olaparib or abemaciclib high-risk brca positive breast cancer?
-
13:51
esmo 2023 breast cancer highlights – keynote 756, tropion-breast01, keynote 52 | onc brothers
-
15:24
breast cancer asco 2022 highlights - oncbrothers (rohit and rahul gosain) with dr. sara tolaney
-
1:00
aphinity update - pertuzumab in her2 breast cancer